What Are Antibody-Drug Conjugates? A Patient Guide

By: David Grew MD MPH

"ADCs are essentially a smart delivery system for chemotherapy."

∗ ∗ ∗

As a radiation oncologist, it hits hard when patients approach the end of the road and conventional treatments stop working.  I often meet patients curious about treatments beyond traditional chemotherapy and radiation. I remember a patient with advanced lung cancer asking, “Is there a therapy that can target only the cancer and spare healthy tissue?”

Antibody-drug conjugates, or ADCs, are an exciting development in this space, designed to deliver potent therapy directly to cancer cells, potentially sparing normal tissues and minimizing side effects. Let’s dive deeper.

How ADCs Work in Cancer Treatment

ADCs are essentially a smart delivery system for chemotherapy. They combine three components: an antibody that seeks out cancer cells, a chemotherapy drug that can kill them, and a linker that holds the two together.

The antibody is designed to recognize a specific protein on the surface of cancer cells, guiding the drug directly to its target. Once the ADC is internalized by the cancer cell, the linker breaks apart, releasing the chemotherapy drug right where it is most needed.

This targeted approach allows the chemotherapy to attack tumors with precision, which can help reduce damage to healthy cells and, in some cases, lessen side effects compared with traditional chemotherapy. Some ADCs are also engineered to release the drug in a way that affects nearby cancer cells, helping treat tumors that may have a mix of cells with and without the target.

Applications and Ongoing Research

ADCs are currently approved for several types of cancer, including certain leukemias, lymphomas, breast cancer, cervical and ovarian cancers, gastrointestinal cancers, bladder cancer, and lung cancer.

Researchers are continuing to explore new targets and develop ADCs for additional cancer types. Treatment is given through IV infusion in a clinic or hospital, with schedules depending on the specific ADC and type of cancer being treated. Side effects can include fatigue, nausea, low blood counts, or organ-specific effects, so careful monitoring is essential.

Ongoing research focuses on identifying new targets, improving the safety of the drug release, and testing different chemotherapy agents to maximize effectiveness. These advances are gradually helping ADCs become a cornerstone of precision cancer care, complementing existing treatments like chemotherapy, targeted therapy, and radiation.

Moving Forward with the Potential Impact of ADCs

The development of ADCs represents a major advance in precision oncology.

For patients with lung cancer and other cancers, ADCs could provide therapies that are more personalized, more targeted, and potentially less toxic than conventional chemotherapy. By focusing treatment on cancer cells while sparing normal tissue, ADCs may improve outcomes for tumors that are difficult to treat or resistant to existing therapies.

As we continue to refine these therapies, ADCs offer a glimpse into a future where cancer treatment is smarter, more effective, and more tailored to the individual patient.

–

To learn more about Antibody-drug Conjugates, watch the video we made here.

To learn more, browse our library of general cancer related topics.

Hire PRIMR to create custom video content for your clinical trial or medical product today.

‍

FAQs:

Could ADCs be combined with other treatments like immunotherapy or radiation?

Yes, combining ADCs with other cancer therapies is an area of active research. Clinical studies are exploring how ADCs can be used alongside immunotherapies, targeted therapies, or radiation to enhance effectiveness. The idea is that ADCs can weaken or shrink tumors while other treatments stimulate the immune system or target resistant cells, potentially improving outcomes without significantly increasing toxicity. However, combination strategies require careful monitoring to manage overlapping side effects, such as low blood counts or organ-specific toxicities.

How do doctors determine which patients are eligible for ADC treatment?

Eligibility for ADC therapy usually depends on the presence of a specific target protein on a patient’s cancer cells, which is detected through laboratory testing of tumor tissue or biopsies. Other factors include cancer type, stage, prior treatments, and overall health. Doctors consider both the potential benefits of the ADC and the patient’s ability to tolerate side effects. This precision approach ensures that ADC therapy is given to patients most likely to benefit while minimizing unnecessary risk.

What are the long-term side effects of ADCs?

Because ADCs are relatively new, long-term side effects are still being studied. Some patients may experience persistent fatigue, neuropathy, or organ-specific effects depending on the ADC used. Blood counts may take longer to recover in some cases, and rare immune reactions can occur. Ongoing clinical trials and real-world monitoring are helping doctors understand and manage these potential long-term effects, ensuring patients receive the safest and most effective care.

‍